Harmony Biosciences Inc (HRMY): Debt to Book Capitalization Ratio

This price chart for Harmony Biosciences (HRMY) illustrates the dynamics of a company currently reducing its reliance on a single product by acquiring projects focused on rare brain pathology therapies. The current indicator stands at 0.21. The business relies on the drug WAKIX, which benefits from patent protection and a unique non-addictive composition; however, profit stability remains tied to the market share of this medication and the success of new developments.

To find fundamental support in Harmony Biosciences (HRMY), it is essential to evaluate the extent to which the development of the neurological portfolio and patent protection rely on equity rather than borrowed funds. By analyzing the total debt-to-equity ratio dynamics on GURU.Markets, an investor determines the proportion of creditor obligations relative to net assets, where low values confirm financial stability and minimize the risk of deep drawdowns.